Nijmegen

• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur
• EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended
  2024-513373-43-00 5 2021-06-11 Short bowel syndrome
• "A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)" Ended
  2023-507146-91-00 5 2021-06-07 Duchenne Muscular Dystrophy (DMD)
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER … Ended
  2024-512012-21-00 5 2021-04-08 Chronic Obstructive Pulmonary Disease
• Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended
  2023-503291-24-00 9 2021-03-17 Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use … Ended
  2023-503771-13-00 4 2021-01-28 Classic Congenital Adrenal Hyperplasia
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended
  2024-512837-34-00 5 2020-10-14 Episodic and Chronic Migraine
• Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer. Ended
  2023-509881-39-00 4 2020-07-27 prostate cancer
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for I … Ended
  2024-516054-21-00 5 2019-10-25 Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Mod
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD) Ended
  2024-512736-29-00 4 2019-08-23 Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)
• OPTIMIZE Ended
  2024-516509-22-00 6 2019-07-22 kidney transplant
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• EASE SBS 2 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome) (SBS) Ended
  2024-513374-22-00 5 2019-04-30 Short Bowel Syndrome
• Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended
  2023-508832-68-00 9 2019-03-28 Recurrent or stage IVB cervical cancer

Showing 529–552 of 568 trials